Church & Dwight Co., Inc. (CHD) gains on deep earnings analysis
Church & Dwight Co., Inc. (CHD) gains despite an EPS miss, as revenue topped estimates and the quarter showed resilient demand, margin pressure, and a constructive outlook. This deep-dive examines the earnings mix, cash flow trends, cost headwinds, and management’s guidance for organic sales and adjusted EPS growth.
Church & Dwight Co., Inc. (CHD) reported a revenue beat of $1.53 billion versus $1.50 billion expected, but adjusted EPS of $0.89 slightly missed consensus. The stock rose 1.16% to $98.81, suggesting investors focused on resilient demand and management’s 2026 outlook for 3% to 4% organic sales growth and 5% to 8% adjusted EPS growth. The miss, along with $25 million to $30 million of incremental inflation pressure, keeps the near-term earnings setup cautious despite a Buy-rated analyst consensus.
Church & Dwight Co., Inc. (CHD) gains as revenue beats and EPS misses. Revenue reached $1.53B against a $1.50B estimate, while EPS came in at $0.89 versus $0.896 expected. The latest regular-session close was $98.81, up 1.16%, on volume of 1,896,649 versus a 2,004,876 average.
Key Takeaways
CHD earnings produced a revenue beat, but EPS of $0.89 missed the $0.896 consensus estimate.
Revenue reached $1.53B, above $1.47B in the March quarter and $1.51B in the year-ago June quarter.
Net income was $0.20B, compared with $0.22B in March, $0.14B in December, and $0.19B in the year-ago quarter.
Specialty Products Division revenue was $299M in 2025, down from $303.3M in 2024.
The detailed 2026 outlook called for organic sales growth of 3% to 4% and adjusted EPS growth of 5% to 8%.
CEO Richard A. Dierker emphasized resilient demand, strong brands, and innovation, while CFO Lee B. McChesney highlighted $25M to $30M of incremental inflation pressure.
Analyst consensus remained Buy, with 18 Buy ratings, 15 Holds, and one Sell.
Financial Performance: Revenue Beat, EPS Miss
The central result in this Church & Dwight Co., Inc. earnings analysis is a split scorecard. Revenue beat the $1.50B estimate by reaching $1.53B. EPS, however, came in at $0.89 against $0.896 expected. That combination points to solid demand, but less conversion from sales into earnings than analysts had modeled.
Sequentially, revenue improved from $1.47B in the quarter ended March 31. It also exceeded the $1.51B recorded in the quarter ended June 30, 2025. Revenue was lower than the $1.59B September result and the $1.64B December result, which reflects the normal variation across CHD's quarterly sales cycle.
The EPS history gives the result more texture. The earnings surprise series shows EPS of $0.95 on May 1, 2026, $0.86 on January 30, $0.81 on October 31, 2025, and $0.94 on August 1, 2025. Therefore, the latest $0.89 figure sits below the May and year-ago results, while remaining above the January and October figures.
Net income of $0.20B also sits below the March figure of $0.22B. Still, it exceeded the $0.14B December result, the $0.18B September result, and the $0.19B year-ago result. The earnings line therefore shows progress across several recent comparisons, even though the latest EPS number missed consensus.
The nearest detailed margin benchmark came from the May 1 quarter. Adjusted gross margin reached 46.4%, up 130 basis points year over year. McChesney attributed 150 basis points to productivity programs, 110 basis points to higher-margin acquisitions and portfolio actions, 50 basis points to volume, price, and mix, and 10 basis points to foreign exchange. Inflation and tariff costs consumed 190 basis points of that benefit.
That prior-quarter bridge matters because CHD faced a similar cost challenge in its broader 2026 outlook. Marketing expense reached 9.5% of sales in the May quarter, while adjusted SG&A increased 110 basis points year over year. The company also reported $174.8M of operating cash flow and $31.9M of capital expenditures in that quarter.
Segment detail remains more limited than the headline revenue figure. The Specialty Products Division generated $299M in 2025, compared with $303.3M in 2024. That decline makes the division a useful counterweight to the broader revenue beat, although the current quarter's $1.53B result does not include a segment split in the reported figures.
Market Reaction and Analyst Response
CHD closed at $98.81, up 1.16%. Volume totaled 1,896,649 shares, below the 2,004,876 average. Because the analysis timestamp fell on August 1, 2026, a Saturday, the quoted market reaction is the July 31 regular-session close at 4:00 PM ET. It is not an after-hours quote or a next-day regular-session move.
The analyst mix remains constructive but far from unanimous. CHD has 18 Buy ratings, 15 Holds, and one Sell, producing an overall Buy consensus. In plain English, the headline label looks positive, but 15 Holds show that many analysts still want stronger evidence before assigning a more aggressive view.
The target records around the report also show a measured setup. StockAnalysis and MarketBeat cited an average target of $103.84, while TipRanks showed $105.40. The broader target range ran from $77 to $115. Barclays carried a Sell rating with an $86 target dated July 21, 2026.
The named rating history includes a Rothschild & Co upgrade on February 13, 2026, and a Morgan Stanley downgrade dated September 9, 2024. Those actions predate the latest print. At $98.81, CHD trades below the $103.84 and $105.40 average targets, but the EPS miss gives cautious analysts a clear reason to resist a rapid re-rating.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
CEO Richard A. Dierker's May 1 comments framed CHD as a value-and-premium portfolio operating through inflation and geopolitical pressure. His message focused on resilient demand and brand strength rather than on a broad consumer rebound.
"The consumer backdrop continues to be mixed. Consumer sentiment remains pressured by inflation, borrowing costs, and geopolitical uncertainty related to the Middle East, which, as you know, is also contributing to significant inflation in commodities and transportation costs. That said, the consumer remains resilient." - Richard A. Dierker, CEO, May 1 earnings call
Dierker also pointed to brand execution. In the May quarter, U.S. consumer organic sales grew 5.4%. TheraBreath gained 3.5 share points to reach 24.1% of total mouthwash, ARM & HAMMER laundry consumption grew 4.1% against category growth of 2.7%, and ARM & HAMMER cat litter consumption grew 6.8%.
CFO Lee B. McChesney supplied the financial frame. He cited the effects of portfolio actions, Toppik, foreign exchange, productivity, and cost inflation. The outlook was designed to absorb a difficult cost environment without abandoning the company's long-term growth model.
"As a result of our mitigating actions, we are reiterating our full year 2026 outlook. We remain on track to deliver full year organic growth of approximately 3% to 4%." - Lee B. McChesney, CFO, May 1 earnings call
McChesney's broader framework included reported sales growth of negative 1.5% to negative 0.5%, gross margin expansion of approximately 100 basis points, marketing at approximately 11% of net sales, and adjusted EPS growth of 5% to 8%. He also estimated $25M to $30M of incremental inflation pressure from the Middle East situation.
Analyst Q&A Highlights
The May 1 CHD earnings call included a revealing exchange with Christopher Michael Carey of Wells Fargo Securities. Carey challenged the durability of volume growth by asking whether distribution gains or inventory reductions drove the quarter.
"When you think about your Q1 delivery, how important are those gains to what we are seeing today, and really speaking to the durability of some of the volume growth that we are seeing relative to perhaps some of the tailwinds that may have been caused by some inventory reductions in the base?" - Christopher Michael Carey, Wells Fargo Securities
Dierker conceded that inventory helped. He said CHD received "a tailwind of a couple of points" from retail inventory dynamics, explaining how the company reached roughly 5% organic growth. That admission matters because it separates temporary assistance from repeatable execution.
"On an average basis over 13 weeks, it is about a 7% TDP lift. In more recent time, as these resets are happening, it is closer to 10% or 11%, which is about double what most of the CPG peers are getting." - Richard A. Dierker, CEO, May 1 earnings call
The response defended distribution as a durable growth lever. Dierker said the gains extended beyond TheraBreath and Hero into laundry, litter, and personal care. He also tied the gains to innovation, including ARM & HAMMER Baking Soda Fresh, laundry sheets, TheraBreath toothpaste, and Hero's Mighty Shield.
Carey then pressed on Toppik, asking about the sustainability of growth and whether the business had room to maintain double-digit consumption growth in the second half and into 2027. The question highlighted a second pressure point in the CHD earnings call: acquired-brand growth must continue after strong launch periods and holiday activity.
Bottom Line
The latest CHD earnings report delivered a clean revenue beat but a modest EPS miss. At $98.81, the stock remains below the $103.84 and $105.40 average targets, while the Buy consensus and the prior guidance framework support a constructive view tempered by cost pressure and uneven segment performance.
+Did Church & Dwight (CHD) beat or miss earnings this quarter?
Church & Dwight beat revenue but missed EPS. Revenue came in at $1.53 billion versus the $1.50 billion estimate, while EPS was $0.89 versus $0.896 expected.
+Why did CHD stock rise even though EPS missed estimates?
CHD shares rose because the company delivered a revenue beat and showed resilient demand across its brands. Investors also appeared to focus on management’s 2026 outlook for 3% to 4% organic sales growth and 5% to 8% adjusted EPS growth.
+What is Church & Dwight's 2026 guidance?
Church & Dwight guided for 3% to 4% organic sales growth in 2026. The company also expects adjusted EPS growth of 5% to 8%.
+What were the main headwinds in CHD's latest earnings report?
Management highlighted $25 million to $30 million of incremental inflation pressure, which weighed on earnings conversion. Specialty Products Division revenue also declined to $299 million in 2025 from $303.3 million in 2024.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
▌The Full Report
Want the full picture on CHD?
The analyst-grade research report — charts, grades, valuation, and price targets — in 10 minutes.
